Target intelligence / Profile preview

L-type voltage-gated calcium channel β1-subunit (Cavβ1)

Target
Cavβ1
Molecular classification
Ion channel auxiliary subunit, Protein complex component, Cytosolic protein
01

Overview

The L-type voltage-gated calcium channel β1-subunit is a cytosolic, non-pore-forming auxiliary protein encoded by the CACNB1 gene. It physically associates with the α1 pore subunit of L-type calcium channels and is vital for proper cell surface expression, assembly, and modulation of channel gating kinetics. Through protein–protein interactions, it regulates calcium influx critical for excitation-contraction coupling in muscle and for cellular signal transduction in excitable tissues. Functional disruption, knockouts, or disease-linked mutations in β1 can lead to severe cardiac or muscular pathophysiology. The β1-subunit is essential for L-type calcium channel function but is not a drug target itself; it is critical for disease biology and underlies many functional and therapeutic properties of the entire channel complex.

Other names
Cavβ1Ca_v_β1Voltage-gated calcium channel β1-subunitβ1-subunit of L-type calcium channel
02

Mechanism of action

For drugs targeting the L-type channel, mechanism includes: Inhibition (blockade) of calcium influx through the α1 subunit β1-subunit increases functional expression and alters gating kinetics, potentially affecting sensitivity to inhibitors

03

Biological functions

Modulation of channel gating (activation and inactivation)Promotion of surface expression and proper trafficking of the α1 subunit of L-type channelsRegulation of excitation–contraction coupling (particularly in cardiac, skeletal, and smooth muscle)Interaction with cellular signaling proteins (e.g., protein kinases, G proteins, RGK GTPases)
04

Disease associations

Cardiovascular diseaseMuscle contraction disordersPotential involvement in neurodegenerative disease (less direct than α1-subunit)Genetic mutations linked to channelopathies
05

Safety considerations

Modulation of cardiac conduction and contraction—risk of arrhythmias if dysregulatedPotential impact on muscle function requiring caution, especially with broad calcium channel therapeutics
06

Interacting drugs

Calcium channel blockers (e.g., dihydropyridines such as nifedipine, amlodipine; verapamil; diltiazem)
07

Biomarkers

Mutations or altered expression of β1-subunit may serve as biomarkers for channelopathies or certain cardiac pathologies, but dedicated clinical biomarkers for patient selection are not well established

Beyond the preview

Go deeper on L-type voltage-gated calcium channel β1-subunit (Cavβ1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-type voltage-gated calcium channel β1-subunit (Cavβ1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call